On Monday 4th November 2024, Medifast (NYSE: MED) will release its highly anticipated third quarter financial results. This important announcement is scheduled to occur after market close.
Financial analysts on Wall Street are predicting that the business is about to reveal an estimated $0.28 loss per share for the quarter. Additionally, the company is projected to announce a total revenue of $134.15 million for this period.
Upon revisiting the corresponding quarter from the prior year, the company's earnings report demonstrated a per-share income of $2.12. This figure was attributed to the company's total revenue, which reached an impressive $235.87 million during that same period.
The company's full-year performance projections, as provided by Wall Street analysts, suggest a total revenue of $607.4 million. Further, they expect the earnings per share to achieve profit of $1.11 for the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.92 | -66.8% | 168.56 M | -43.1% |
| Q1 2024 | $0.66 | -82.0% | 174.74 M | -49.9% |
| Q4 2023 | $1.09 | -70.5% | 191.02 M | -43.4% |
| Q3 2023 | $2.12 | -36.1% | 235.87 M | -39.6% |
| Q2 2023 | $2.77 | -28.4% | 296.19 M | -34.7% |
| *Growth on year-over-year basis | ||||
Additionally, The company will host a conference call with investors and analysts on 4th November 2024 at 04:30 PM eastern time to review the Q3 2024 financial results.
Medifast (MED) shares traded as low as $18.49 and as high as $19.17 on a day volume of 170.40 thousand shares, closed Friday's regular trading session at $18.58, a rise of 1.09 percent.
